Natural T cell immunity against cancer

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4296-4303

  Nagorsen, Dirk ^a   Scheibenbogen, Carmen ^b   Marincola, Francesco M ^a   Letsch, Anne ^b   Keilholz, Ulrich ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; MYELOBLASTIN; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; TUMOR PROTEIN; UNCLASSIFIED DRUG; WILM TUMOR PROTEIN;

ANTIGEN DETECTION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; LEUKEMIA; MELANOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN FAMILY; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; HUMANS; IMMUNITY, CELLULAR; NEOPLASMS; T-LYMPHOCYTES;

EID: 0141960452     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC), 254: 1643-1647, 1991.
2. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
3. Renkvist, N., Castelli, C., Robbins, P. F., and Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother., 50: 3-15, 2001.
4. Smyth, M. J., Godfrey, D. I., and Trapani, J. A. A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol., 2: 293-299, 2001.
5. Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., and Anichini, A. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. (Bethesda), 94: 805-818, 2002.
6. Molldrem, J. J., Lee, P. P., Wang, C., Felio, K., Kantarjian, H. M., Champlin, R. E., and Davis, M. M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med., 6: 1018-1023, 2000.
7. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., and Fay, J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res., 61: 6451-6458, 2001.
8. Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M. R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni, G., Lombardo, C., Arienti, F., Marchiano, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J. J., Srivastava, P., and Parmiani, G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol., 20: 4169-4180, 2002.
9. Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., Lyerly, H. K., Lee, P. P., Storkus, W., Marincola, F., Worobec, A., and Atkins, M. B. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother., 25: 97-138, 2002.
10. Monsurro, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M. E., Rosenberg, S. A., and Marincola, F. M. Functional heterogeneity of vaccine-induced CD8(+) T cells. J. Immunol., 168: 5933-5942, 2002.
11. Suni, M. A., Picker, L. J., and Maino, V. C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods, 212: 89-98, 1998.
12. Scheibenbogen, C., Lee, K. H., Mayer, S., Stefanovic, S., Moebius, U., Herr, W., Rammensee, H. G., and Keilholz U. A sensitive Elispot assay for detection of CD8+ lymphocytes specific for HLA class I-peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin. Cancer Res., 3: 221-226, 1997.
13. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes [erratum in Science (Wash. DC), 280: 1821, 1998]. Science (Wash. DC), 274: 94-96, 1996.
14. Altman, J. D., Moss, P. A., Goulder, P. J., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes [erratum in Science (Wash. DC), 280: 1821, 1998]. Science (Wash. DC), 274: 94-96, 1996.
15. Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol., 163: 6292-6300, 1999.
16. Nielsen, M. B., Monsurro, V., Migueles, S. A., Wang, E., Perez-Diez, A., Lee, K. H., Kammula, U., Rosenberg, S. A., and Marincola, F. M. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol., 165: 2287-2296, 2000.
17. Hamann, D., Roos, M. T., and van Lier, R. A. Faces and phases of human CD8 T cell development. Immunol. Today, 20: 177-180, 1999.
18. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (Lond.), 401: 708-712, 1999.
19. Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., Little, S., Havlir, D. V., Richman, D. D., Gruener, N., Pape, G., Waters, A., Easterbrook, P., Salio, M., Cerundolo, V., McMichael, A. J., and Rowland-Jones, S. L. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med., 8: 379-385, 2002.
20. Scheibenbogen, C., Lee, K. H., Stevanovic, S., Witzens, M., Willhauck, M., Waldmann, V., Naeher, H., Rammensee, H. G., and Keilholz, U. Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay. Int. J. Cancer, 71: 932-936, 1997.
21. Pittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Lienard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J. C., and Romero, P. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med., 190: 705-715, 1999.
22. Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., Roederer, M., and Davis, M. M. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med., 5: 677-685, 1999.
23. Dhodapkar, M. V., Young, J. W., Chapman, P. B., Cox, W. I., Fonteneau, J. F., Amigorena, S., Houghton, A. N., Steinman, R. M., and Bhardwaj, N. Paucity of functional T cell memory to melanoma antigens in healthy donors and melanoma patients. Clin. Cancer Res., 6: 4831-4838, 2000.
24. Griffioen, M., Borghi, M., Schrier, P. I., and Osanto, S. Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-γ-ELISPOT assay. Int. J. Cancer, 93: 549-555, 2001.
25. Pittet, M. J., Zippelius, A., Valmori, D., Speiser, D. E., Cerottini, J. C., and Romero, P. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol., 23: 325-328, 2002.
26. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J. L., Lienard, D., Cerottini, J. C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
27. Valmori, D., Scheibenbogen, C., Dutoit, V., Nagorsen, D., Asemissen, A. M., Rubio-Godoy, V., Rimoldi, D., Guillaume, P., Romero, P., Schadendorf, D., Lipp, M., Dietrich, P. Y., Thiel, E., Cerottini, J. C., Lienard, D., and Keilholz, U. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res., 62: 1743-1750, 2002.
28. Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z., Boisvert, J., Greenberg, H. B., Vierra, M. A., Goodman, S. B., Genovese, M. C., Wardlaw, A. J., Butcher, E. C., and Wu, L. CCR7 expression and memory T cell diversity in humans. J. Immunol., 166: 877-884, 2001.
29. Yamshchikov, G., Thompson, L., Ross, W. G., Galavotti, H., Aquila, W., Deacon, D., Caldwell, J., Patterson, J. W., Hunt, D. F., and Slingluff, C. L., Jr. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations. Clin. Cancer Res., 7 (Suppl.): 909s-916s, 2001.
30. Valmori, D., Dutoit, V., Lienard, D., Rimoldi, D., Pittet, M. J., Champagne, P., Ellefsen, K., Sahin, U., Speiser, D., Lejeune, F., Cerottini, J. C., and Romero, P. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res., 60: 4499-4506, 2000.
31. Jager, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jager, D., Arand, M., Ritter, G., Cerundolo, V., Dupont, B., Chen, Y. T., Old, L. J., and Knuth, A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA, 97: 4760-4765, 2000.
32. Traversari, C., van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176: 1453-1457, 1992.
33. Gaugler, B., Van den Eynde, B., van der Bruggen, P., Romero, P., Gaforio, J. J., De Plaen, E., Lethe, B., Brasseur, F., and Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179: 921-930, 1994.
34. van der Bruggen, P., Szikora, J. P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T. Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601. Eur. J. Immunol., 24: 2134-2140, 1994.
35. Chaux, P., Vantomme, V., Coulie, P., Boon, T., and van der Bruggen, P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer, 77: 538-542, 1998.
36. Zorn, E., and Hercend, T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur. J. Immunol., 29: 602-607, 1999.
37. Valmori, D., Dutoit, V., Rubio-Godoy, V., Chambaz, C., Liénard, D., Guillaume, P., Romero, P., Cerottini, J. C., and Rimoldi, D. Frequent cytolytic T cell responses to peptide MAGE-A10 254-262 in melanoma. Cancer Res., 61: 509-512, 2001.
38. Rimoldi, D., Rubio-Godoy, V., Dutoit, V., Lienard, D., Salvi, S., Guillaume, P., Speiser, D., Stockert, E., Spagnoli, G., Servis, C., Cerottini, J. C., Lejeune, F., Romero, P., and Valmori, D. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J. Immunol., 165: 7253-7261, 2000.
39. Andersen, M. H., Pedersen, L. O., Capeller, B., Brocker, E. B., Becker, J. C., and thor Straten, P. Spontaneous cytotoxic T cell responses against survivin-derived MHC class I-restricted T cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res., 61: 5964-5968, 2001.
40. Letsch, A., Keilholz, U., Schadendorf, D., Nagorsen, D., Schmittel, A., Thiel, E., and Scheibenbogen C. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma. Int. J. Cancer, 87: 659-664, 2000.
41. Anichini, A., Mortarini, R., Maccalli, C., Squarcina, P., Fleischhauer, K., Mascheroni, L., and Parmiani, G. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J. Immunol., 56: 208-217, 1996.
42. + memory T cells. Cancer Res., 63: 5582-5586, 2003.
43. Titu, L. V., Monson, J. R., and Greenman, J. The role of CD8(+) T cells in immune responses to colorectal cancer. Cancer Immunol. Immunother., 51: 235-247, 2002.
44. Nagorsen, D., Keilholz, U., Rivoltini, L., Schmittel, A., Letsch, A., Asemissen, A. M., Berger, G., Buhr, H. J., Thiel, E., and Scheibenbogen, C. Natural T cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res., 60: 4850-4854, 2000.
45. Nagorsen, D., Scheibenbogen, C., Schaller, G., Leigh, B., Schmittel, A., Letsch, A., Thiel, E., and Keilholz, U. Differences in T cell immunity towards tumor associated antigens between colorectal cancer and breast cancer. Int. J. Cancer, 105: 221-225, 2003.
46. Hamann, D., Baars, P. A., Rep, M. H., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., and van Lier, R. A. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med., 186: 1407-1418, 1997.
47. Arlen, P., Tsang, K. Y., Marshall, J. L., Chen, A., Steinberg, S. M., Poole, D., Hand, P. H., Schlom, J., and Hamilton, J. M. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol. Immunother., 49: 517-529, 2000.
48. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER-2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
49. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
50. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
51. Disis, M. L., Knutson, K. L., Schiffman, K., Rinn, K., and McNeel, D. G. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res. Treat, 62: 245-252, 2000.
52. Feuerer, M., Beckhove, P., Bai, L., Solomayer, E. F., Bastert, G., Diel, I. J., Pedain, C., Oberniedermayr, M., Schirrmacher, V., and Umansky, V. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat. Med., 7: 452-458, 2001.
53. Diel, I. J., and Cote, R. J. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat. Rev., 26: 53-65, 2000.
54. Hoffmann, T. K., Donnenberg, A. D., Finkelstein, S. D., Donnenberg, V. S., Friebe-Hoffmann, U., Myers, E. N., Appella, E., DeLeo, A. B., and Whiteside, T. L. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res., 62: 3521-3529, 2002.
55. Burchert, A., Wolfl, S., Schmidt, M., Brendel, C., Denecke, B., Cai, D., Odyvanova, L., Lahaye, T., Muller, M. C., Berg, T., Gschaidmeier, H., Wittig, B., Hehlmann, R., Hochhaus, A., and Neubauer, A. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T cell response in chronic myeloid leukemia. Blood, 101: 259-264, 2003.
56. Scheibenbogen, C., Letsch, A., Thiel, E., Schmittel, A., Mailaender, V., Baerwolf, S., Nagorsen, D., and Keilholz, U. CD8 T cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood, 100: 2132-2137, 2002.
57. Andersen, M. H., Pedersen, L. O., Becker, J. C., and Straten, P. T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res., 61: 869-872, 2001.
58. Greco, G., Fruci, D., Accapezzato, D., Barnaba, V., Nisini, R., Alimena, G., Montefusco, E., Vigneti, E., Butler, R., Tanigaki, N., and Tosi, R. Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia (Baltimore), 10: 693-699, 1996.
59. Osman, Y., Takahashi, M., Zheng, Z., Koike, T., Toba, K., Liu, A., Furukawa, T., Aoki, S., and Aizawa, Y. Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia (Baltimore), 13: 166-174, 1999.
60. Wagner, W. M., Ouyang, Q., and Pawelec, G. Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia. Leukemia (Baltimore), 16: 2341-2343, 2002.
61. Khanna, R., and Burrows, S. R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol., 54: 19-48, 2000.
62. Bontkes, H. J., de Gruijl, T. D., van den Muysenberg, A. J., Verheijen, R. H., Stukart, M. J., Meijer, C. J., Scheper, R. J., Stacey, S. N., Duggan-Keen, M. F., Stern, P. L., Man, S., Borysiewicz, L. K., and Walboomers, J. M. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int. J. Cancer, 88: 92-98, 2000.
63. Youde, S. J., Dunbar, P. R., Evans, E. M., Fiander, A. N., Borysiewicz, L. K., Cerundolo, V., and Man, S. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res., 60: 365-371, 2000.
64. Wilkinson, J., Cope, A., Gill, J., Bourboulia, D., Hayes, P., Imami, N., Kubo, T., Marcelin, A., Calvez, V., Weiss, R., Gazzard, B., Boshoff, C., and Gotch, F. Identification of Kaposi's sarcoma-associated herpes-virus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J. Virol., 76: 2634-2640, 2002.
65. Boshoff, C., and Weiss R. AIDS-related malignancies. Nat. Rev. Cancer, 2: 373-382, 2002.
66. Hsieh, W. S., Lemas, M. V., and Ambinder, R. F. The biology of Epstein-Barr virus in post-transplant lymphoproliferative disease. Transpl. Infect. Dis., 1: 204-212, 1999.
67. Karanikas, V., Colau, D., Baurain, J. F., Chiari, R., Thonnard, J., Gutierrez-Roelens, I., Goffinet, C., Van Schaftingen, E. V., Weynants, P., Boon, T., and Coulie, P. G. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res., 61: 3718-3724, 2001.
68. Echchakir, H., Mami-Chouaib, F., Vergnon, I., Baurain, J. F., Karanikas, V., Chouaib, S., and Coulie, P. G. A point mutation in the α-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 61: 4078-4083, 2001.
69. Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K. H., Wernet, D., Stevanovic, S., and Rammensee, H. G. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res., 62: 5818-5827, 2002.
70. Chen, Q., Jackson, H., Gibbs, P., Davis, I. D., Trapani, J., and Cebon, J. Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects. Cancer Immunol. Immunother., 47: 191-197, 1998.
71. Marincola, F. M., Rivoltini, L., Salgaller, M. L., Player, M., and Rosenberg, S. A. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J. Immunother. Emphasis Tumor Immunol., 19: 266-277, 1996.
72. Loftus, D. J., Squarcina, P., Nielsen, M. B., Geisler, C., Castelli, C., Odum, N., Appella, E., Parmiani, G., and Rivoltini, L. Peptides derived from self-proteins as partial agonists and antagonists of human CD8+ T cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res., 58: 2433-2439, 1998.
73. Ogg, G. S., Rod Dunbar, P., Romero, P., Chen, J. L., and Cerundolo, V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J. Exp. Med., 188: 1203-1208, 1998.
74. Lang, K. S., Caroli, C. C., Muhm, A., Wernet, D., Moris, A., Schittek, B., Knauss-Scherwitz, E., Stevanovic, S., Rammensee, H. G., and Garbe, C. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART-1. J. Investig. Dermatol., 116: 891-897, 2001.
75. Stockinger, B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol., 71: 229-265, 1999.
76. Molldrem, J. J., Lee, P. P., Kant, S., Wieder, E., Jiang, W., Lu, S., Wang, C., and Davis, M. M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Investig., 111: 639-647, 2003.
77. Dutoit, V., Taub, R. N., Papadopoulos, K. P., Talbot, S., Keohan, M. L., Brehm, M., Gnjatic, S., Harris, P. E., Bisikirska, B., Guillaume, P., Cerottini, J. C., Hesdorffer, C. S., Old, L. J., and Valmori, D. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Investig., 110: 1813-1822, 2002.
78. Valmori, D., Pittet, M. J., Vonarbourg, C., Rimoldi, D., Lienard, D., Speiser, D., Dunbar, R., Cerundolo, V., Cerottini, J. C., and Romero, P. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res., 59: 4050-4055, 1999.
79. Naito, Y., Saito, K., Shiiba, K., Ohuchi, A., Saigenji, K., Nagura, H., and Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res., 58: 3491-3494, 1998.
80. Schumacher, K., Haensch, W., Roefzaad, C., and Schlag, P. M. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res., 61: 3932-3936, 2001.
81. Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., and Coukos, G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med., 348: 203-213, 2003.
82. Marincola, F. M., Jaffee, E. M., Hicklin, D. J., and Ferrone, S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74: 181-273, 2000.
83. Pupa, S. M., Menard, S., Andreola, S., and Colnaghi, M. I. Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res., 53: 5864-5866, 1993.
84. Fishman, P., Merimski, O., Baharav, E., and Shoenfeld, Y. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer (Phila.), 79: 1461-1464, 1997.
85. Mosolits, S., Harmenberg, U., Ruden, U., Ohman, L., Nilsson, B., Wahren, B., Fagerberg, J., and Mellstedt, H. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother., 47: 315-320, 1999.
86. Jager, E., Stockert, E., Zidianakis, Z., Chen, Y. T., Karbach, J., Jager, D., Arand, M., Ritter, G., Old, L. J., and Knuth A. Humoral immune response of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer, 84: 506-510, 1999.
87. Gao, F. G., Khammanivong, V., Liu, W. J., Leggatt, G. R., Frazer, I. H., and Fernando, G. J. Antigen-specific CD4+ T cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res., 62: 6438-6441, 2002.
88. McNeel, D. G., Nguyen, L. D., Ellis, W. J., Higano, C. S., Lange, P. H., and Disis, M. L. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate, 47: 222-229, 2001.
89. Gaiger, A., Carter, L., Greinix, H., Carter, D., McNeill, P. D., Houghton, R. L., Cornellison, C. D., Vedvick, T. S., Skeiky, Y. A., and Cheever, M. A. WT1 specific serum antibodies in patients with leukemia. Clin. Cancer Res.; 7 (Suppl.): 761s-765s, 2001.